"10.1371_journal.pone.0097929","plos one","2014-06-02T00:00:00Z","Alexander Pretsch; Michael Nagl; Katja Schwendinger; Birgit Kreiseder; Martina Wiederstein; Dagmar Pretsch; Miroslav Genov; Ralph Hollaus; Daniela Zinssmeister; Abdesamad Debbab; Harald Hundsberger; Andreas Eger; Peter Proksch; Christoph Wiesner","SeaLife Pharma GmbH, Tulln, Austria; Medical and Pharmaceutical Biotechnology, University of Applied Sciences, Krems, Austria; Institute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine University, Düsseldorf, Germany","Conceived and designed the experiments: AP CW. Performed the experiments: AP MN KS BK MW DP RH DZ HH CW. Analyzed the data: AP MG CW. Contributed reagents/materials/analysis tools: AD HH AE PP. Wrote the paper: MN CW.","SeaLife Pharma GmbH holds the patent for the Anthracene derivatives (“Neue Tetrahydroanthracenon-Derivate”; WO 2010135758 A1; compound AA ´) isolated from T. wortmannii. A. Pretsch, P. Proksch, and A. Debbab are the inventors of the patent and SeaLife Pharma GmbH is the patent holder. In the next two years, SeaLife GmbH plans to market and commercialize the T. wortmannii extract as a cosmetic product. A. Pretsch (Head of Microbiology and CEO), M. Nagl (Head of Chemistry), K. Schwendinger (Master Student), B. Kreiseder (Junior Scientist), M. Wiederstein (Junior Scientist), D. Pretsch (Junior Scientist), D. Zinssmeister (Master Student), M. Genov (Senior Scientist), R. Hollaus (Junior Scientist), and C. Wiesner (CSO) are all employed at SeaLife Pharma GmbH. Beside the product above, SeaLife Pharma GmbH is developing (pre-clinical studies) an anti-infective Anthraquinone-Derivative (patent in preparation) for the treatment of MRSA. Up to now, SeaLife Pharma has no products on the market. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2014","06","Alexander Pretsch","AP",14,TRUE,2,10,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
